Sign in
Taking people in United StatesPhase 1

Tests how body composition affects IVIG and SCIG treatment for CIDP

Compares intravenous and subcutaneous immune globulin in adults with CIDP.

Key facts

Who runs it
Rutgers, The State University of New Jersey
Where
New Brunswick, United StatesSee the site
Trial code
Registry title
IVIG vs SCIG in CIDP
Status
Recruiting
Phase
Phase 1
People taking part
20 people, planned
Started
11 Sept 2022
Expected to end
1 Dec 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Intravenous immune globulin G
  • Subcutaneous immune globulin G
Record updated
11 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with CIDP who receive immunoglobulin G (IVIG) and can switch to the subcutaneous form (SCIG) at a set weekly dose.

Age
Over 18 years, up to 65 years.
Sex
All sexes can join.
Disease stage
A current diagnosis of CIDP, based on the European Federation of Neurological sciences / Peripheral Nerve Society CIDP diagnostic criteria.
Earlier treatment
Current IVIG treatment. A 1:1 weekly dose conversion from IVIG to SCIG must fall within 0.2-to-0.4 mg/kg for SCIG.

Main reasons for not taking part

  • Receiving IVIG for something other than CIDP
  • Liver problems (liver enzymes more than 3 times the upper limit of normal)
  • Reduced kidney function (CrCl < 50 mL/min)
  • Active cancer
  • Diabetes, myasthenia gravis, immunodeficiency or autoimmune disease

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients aged >18 years with a current diagnosis of CIDP (based on European Federation of Neurological sciences / Peripheral Nerve Society CIDP diagnostic criteria)
  • 1:1 conversion of IVIG to SCIG (weekly dose conversion) must fall within 0.2-to-0.4 mg/kg dose for SCIG

Who cannot take part

  • Patients receiving IVIG for indications other than CIDP will be excluded
  • Patients with liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal) or reduced renal function (CrCl < 50 mL/min) will be excluded
  • Active malignancies
  • Diabetes
  • Autoimmune disease
  • Myasthenia gravis
  • Immunodeficiency

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • Rutgers, The State University of New Jersey Clinical Research CenterNew Brunswick, United StatesContact: Luigi Brunetti, PhDTaking people

About the trial

What the trial wants to find out

Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.

The 2 groups in the trial

  • Intravenous immune globulin GTreatment being tested

    Subjects will receive there current intravenous immune globulin dose.

  • Subcutaneous immune globulin GTreatment being tested

    The dosage will be converted from the subject's current intravenous immune globulin G dosage 1:1 (gm per gm).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration
Plain-language title
Tests how body composition affects IVIG and SCIG treatment for CIDPGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05584631, who can take part
Record updated
11 December 2025